Publicaciones en colaboración con investigadores/as de Hospital Universitario de Valme (92)

2024

  1. Clinical Presentation and Outcomes of Patients with Cancer-Associated Isolated Distal Deep Vein Thrombosis

    Journal of Clinical Oncology, Vol. 42, Núm. 5, pp. 529-537

  2. Clustering COVID-19 ARDS patients through the first days of ICU admission. An analysis of the CIBERESUCICOVID Cohort

    Critical Care, Vol. 28, Núm. 1

  3. Whole-genome characterisation of Escherichia coli isolates from patients with bacteraemia presenting with sepsis or septic shock in Spain: a multicentre cross-sectional study

    The Lancet Microbe, Vol. 5, Núm. 4, pp. e390-e399

2023

  1. A blood microRNA classifier for the prediction of ICU mortality in COVID-19 patients: a multicenter validation study

    Respiratory Research, Vol. 24, Núm. 1

  2. A differential therapeutic consideration for use of corticosteroids according to established COVID-19 clinical phenotypes in critically ill patients

    Medicina Intensiva, Vol. 47, Núm. 1, pp. 23-33

  3. Conventional Hospitalization versus Sequential Outpatient Parenteral Antibiotic Therapy for Staphylococcus aureus Bacteremia: Post-Hoc Analysis of a Multicenter Observational Cohort

    Antibiotics, Vol. 12, Núm. 1

  4. Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study

    The Lancet Microbe, Vol. 4, Núm. 6, pp. e431-e441

  5. Effects of intubation timing in patients with COVID-19 throughout the four waves of the pandemic: a matched analysis

    The European respiratory journal, Vol. 61, Núm. 3

  6. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

  7. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients

    Intensive Care Medicine, Vol. 49, Núm. 8, pp. 934-945

  8. Risk factors for developing ventilator-associated lower respiratory tract infection in patients with severe COVID-19: a multinational, multicentre study, prospective, observational study

    Scientific reports, Vol. 13, Núm. 1, pp. 6553

2022

  1. Clindamycin but not Intravenous Immunoglobulins reduces mortality in a retrospective cohort of critically ill patients with bacteremic Group A Streptococcal infections

    Revista Espanola de Quimioterapia, Vol. 35, Núm. 5, pp. 475-481

  2. Dexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19

    Journal of Critical Care, Vol. 69

  3. Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021)

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 1, pp. 36-55

  4. Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: A cohort study

    F1000Research, Vol. 11

  5. Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis

    Dermatologic Therapy, Vol. 35, Núm. 10

  6. Guselkumab dosing interval optimization in adult patients with moderate-to-severe psoriasis switching from ustekinumab

    Dermatologic Therapy, Vol. 35, Núm. 11

  7. In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study

    Frontiers in Cellular and Infection Microbiology, Vol. 12

  8. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study

    Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864

  9. Methodology of a Large Multicenter Observational Study of Patients with COVID-19 in Spanish Intensive Care Units

    Archivos de Bronconeumologia, Vol. 58, pp. 22-31